JPX · 4523.T
Eisai Co., Ltd.
¥5,052+¥78 (+1.57%)
Eisai Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 3.64% below the high.
Loading market information…
JPX · 4547.T · JPY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
Kissei Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 24.5% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Kissei Pharmaceutical Co., Ltd.’s forward annual dividend is ¥105 per share, paid annual. The forward yield is 2.76% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Kissei Pharmaceutical Co., Ltd.’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of ¥34. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Kissei Pharmaceutical Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Kissei Pharmaceutical Co., Ltd. specializes in the discovery, development, production, and commercialization of pharmaceutical products, with a primary focus on the Japanese market. Its marketed pharmaceuticals encompass Urief and Urief OD tablets, designed to alleviate dysuria. For type 2 diabetes, it provides Glufast, Glubes, and Marizev tablets. Treating renal anemia, the company offers Darbepoetin Alfa BS and Epoetin Alfa BS injections. Beova tablets are available for managing overactive bladder, while hyperphosphatemia patients can utilize P-TOL chewable tablets. Furthermore, Minirin Melt OD tablets address a range of conditions including nocturia caused by nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis stemming from reduced urine osmolality. Kissei maintains a robust product pipeline, featuring KPS-0373, which has successfully completed Phase III clinical trials for spinocerebellar ataxia, and CCX168, also a completed Phase III candidate, targeting microscopic polyangiitis and granulomatosis with polyangiitis. Currently undergoing Phase III trials are AJM300 for ulcerative colitis, R788 for chronic idiopathic thrombocytopenic purpura, and MR13A9 to alleviate uremic pruritus in dialysis patients. Other investigational compounds include KLH-2109 for endometriosis and uterine fibroids, KDT-3594 for Parkinson's disease, Silodosin addressing dysuria linked to benign prostatic hyperplasia, Mitiglinide for type 2 diabetes mellitus, and Bedoradrine for the management of acute asthma exacerbations. Beyond its pharmaceutical endeavors, Kissei also manufactures and markets specialized nutritional products, such as protein-controlled and energy-supplying foods, and engages in the procurement and sale of associated raw materials. Furthermore, the company extends its operations to include system development, information processing, construction services, equipment and facility oversight, alongside information collection and development assistance. Founded in 1946 as Kissei Yakuhin Kogyo Co., Ltd., the company adopted its present name, Kissei Pharmaceutical Co., Ltd., in October 1964. Its corporate headquarters are situated in Matsumoto, Japan.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:33 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2025 | May 7, 2025 | ¥73+16.83% vs estimate | ¥22.66B+12.51% vs estimate |
|---|
| Q3 2025 | Feb 3, 2025 | ¥83-2.79% vs estimate | ¥23.2B+6.51% vs estimate |
|---|
| Q2 2025 | Nov 5, 2024 | ¥26-66.47% vs estimate | ¥21.3B+3.91% vs estimate |
|---|
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
¥5,052+¥78 (+1.57%)
Eisai Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 3.64% below the high.
¥2,256+¥32 (+1.42%)
Ono Pharmaceutical Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 15.65% below the high.
¥3,436+¥18 (+0.53%)
Nippon Shinyaku Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 47.37% below the high.
¥3,520+¥60 (+1.73%)
Towa Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 21.6% below the high.
¥3,830+¥30 (+0.79%)
Kaken Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 13.84% below the high.
¥3,285+¥45 (+1.39%)
Mochida Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 17.15% below the high.
¥1,977+¥36 (+1.85%)
Zeria Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 18.78% below the high.
¥544+¥33 (+6.46%)
JCR Pharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 33.98% below the high.
